Chicago, Sept. 08, 2022 (GLOBE NEWSWIRE) -- According to the new market research report "Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), & Region (NA, Europe, APAC) - Global Forecasts to 2026", is projected to reach USD 48.9 billion by 2026 from USD 31.8 billion in 2021, at a CAGR of 9.0% during the forecast period.
Browse in-depth TOC on "Prostate Health Market"
124 - Tables
11 - Figures
99 - Pages
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107055093
The prostate gland (the prostate) is an organ of the male reproductive system. The three most common forms of prostate disease are inflammation (prostatitis), non-cancerous enlargement of the prostate (benign prostatic hyperplasia or BPH), and prostate cancer. Benign prostatic hyperplasia (BPH) is defined as a medical condition affecting men. It involves the non-cancerous enlargement of the prostate gland. While BPH rarely shows symptoms before the age of 40, the risk of contracting BPH increases with age. The condition affects nearly 50% of men between the ages of 51 and 60 and up to 90% of men older than 80. Treatment measures such as medications and surgery have been used for patients with BPH.
In this report, the prostate health market has been segmented based on type, application, mode of purchase, and region.
Based on disease indication, the market is segmented into prostate cancer, benign prostate hyperplasia, and prostatitis. In 2020, prostate cancer accounted for the largest sharein the prostate health market. Typically, hormone therapy is considered an effective option as the first line of treatment for prostate cancer. Cancer vaccines, radiopharmaceutical agents, secondary hormone therapies, or chemotherapies follow hormonal therapy as treatment options. Cancerous cells are found to be developing a resistance to these therapies after some months, as a result of which immunotherapies are expected to be adopted widely for the treatment of prostate cancer in the near future.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=107055093
Geographical Growth Scenario:
The prostate health market is segmented into regions—North America, Europe, AsiaPacific, Latin America, and Middle East & Africa. North America has been among the frontrunners in developingprostate healththerapies in the healthcare industry. The market growth in the US (a major contributor to the North American market) can be mainly attributed to the growing target population, the high incidence of BPH, prostate cancer, and prostatitis, and the strong presence of medical device manufacturers. Additionally, favorable reimbursement policies, high disposable incomes, a strong healthcare infrastructure, research funding, and product launches have accelerated the growth of this market.
Key Players:
Some of the prominent players operating in the prostate health market are Eli Lilly and Company (US), Pfizer Inc. (US), Merck & Co., Inc. (US), GlaxoSmithKline plc. (UK), Abbott (US), and Astellas Pharma Inc. (Japan), and other players.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=107055093
Browse Adjacent Markets: Pharmaceuticals Market Research Reports & Consulting
Browse Related Reports:
Cancer Diagnostics Market by Product (Consumables (Anitibodies, Probes), Instruments (Pathology Instruments, Imaging Instruments, Biopsy), Technology (IVD Testing), Application (Breast Cancer, Lung Cancer), End User (Hospitals) (2022 - 2026)
Cancer/Tumor Profiling Market by (Technology (Immunoassay, NGS, PCR, In-Situ Hybridization, Microarray), Cancer Type (Breast, Lung, Colorectal, Prostate, Melanoma)), Biomarker Type (Genomic, Protein), Application, Region - Global Forecast to 2025
